Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569812 | 0.94 | ALDH1A1 (0.53) | ALDH1A1TSHRMMP8SMN1; SMN2MEN1 | |
| SCHEMBL18424616 | 0.89 | ALDH1A1 (0.48) | ALDH1A1TSHRMMP8SMN1; SMN2MEN1 | |
| SCHEMBL5846343 | 0.88 | HDAC3 (0.52) | ALDH1A1TSHRMMP8SMN1; SMN2KMT2A | |
| SCHEMBL8990085 | 0.86 | ALDH1A1 (0.46) | ALDH1A1TSHRMMP8SMN1; SMN2MEN1 | |
| SCHEMBL7061793 | 0.86 | TSHR (0.49) | ALDH1A1TSHRMMP8SMN1; SMN2MEN1 | |
| SCHEMBL2291948 | 0.85 | MMP8 (0.56) | ALDH1A1TSHRMMP8SMN1; SMN2CNR2 | |
| SCHEMBL2427317 | 0.84 | MMP8 (0.54) | ALDH1A1TSHRMMP8SMN1; SMN2MEN1 | |
| SCHEMBL7059676 | 0.84 | ALDH1A1 (0.56) | ALDH1A1TSHRMMP8SMN1; SMN2KMT2A | |
| SCHEMBL7062265 | 0.84 | HCAR2 (0.47) | ALDH1A1TSHRMMP8SMN1; SMN2HPGD | |
| SCHEMBL7060890 | 0.83 | TSHR (0.50) | ALDH1A1TSHRMMP8SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100425636-C | Polyalkylene terephthalate and process for producing the same | ASAHI CHEMICAL CORP (JP) | 2008-10-15 | — | — | CN | disclosed |
| US-20080171792-A1 | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders | PROVIDENT BANK | 2008-07-17 | — | — | US | disclosed |
| US-20070004805-A1 | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate | NAVINTA LLC | 2007-01-04 | — | — | US | disclosed |
| CN-1867606-A | Process for producing polyalkylene terephthalate, process for producing polyalkylene terephthalate molding and polyalkylene terephthalate molding | ASAHI CHEMICAL CORP (JP) | 2006-11-22 | — | — | CN | disclosed |
| WO-2004096808-A1 | TRIAZINE COMPOUNDS AND THEIR USE | DE NOVO PHARMACEUTICALS LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004805-A1 | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate | PDHB, CYP4B1, GABRB1 | ALDH1A1 1000/4885TSHR 4134/4885MMP8 4616/4885 |
| US-20080171792-A1 | Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders | SMN1; SMN2, ABAT, PMP22 | ALDH1A1 991/4885TSHR 4792/4885MMP8 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.